METTL3 and cancer: METTL3 acts on the reader IGF2BP2, and IGF2BP2 directly binds to a specific m6A site of in SOX2 CDS and controls the half-life of SOX2 mRNA by relying on m6A modification to produce cancer-promoting effects [63].